Intervention Review

You have free access to this content

Pharmacotherapy for the prevention of chronic pain after surgery in adults

  1. Luis Enrique Chaparro1,
  2. Shane A Smith2,
  3. R Andrew Moore3,
  4. Philip J Wiffen3,
  5. Ian Gilron4,*

Editorial Group: Cochrane Pain, Palliative and Supportive Care Group

Published Online: 24 JUL 2013

Assessed as up-to-date: 17 JUL 2013

DOI: 10.1002/14651858.CD008307.pub2


How to Cite

Chaparro LE, Smith SA, Moore RA, Wiffen PJ, Gilron I. Pharmacotherapy for the prevention of chronic pain after surgery in adults. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD008307. DOI: 10.1002/14651858.CD008307.pub2.

Author Information

  1. 1

    Hospital Pablo Tobon Uribe, Anesthesiology Department, Medellin, Colombia

  2. 2

    Queen's University, Department of Anesthesiology & Perioperative Medicine, Kingston, Canada

  3. 3

    University of Oxford, Pain Research and Nuffield Department of Clinical Neurosciences, Oxford, Oxfordshire, UK

  4. 4

    Queen's University, Departments of Anesthesiology & Perioperative Medicine & Biomedical & Molecular Sciences, Kingston, Ontario, Canada

*Ian Gilron, Departments of Anesthesiology & Perioperative Medicine & Biomedical & Molecular Sciences, Queen's University, 76 Stuart Street, Victory 2 Pavillion, Kingston, Ontario, K7L 2V7, Canada. gilroni@queensu.ca.

Publication History

  1. Publication Status: New
  2. Published Online: 24 JUL 2013

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 4]
Figure 4. Forest plot of comparison: 1 Ketamine versus placebo comparisons, outcome: 1.5 Incidence of any pain at 6 months (all studies).
[Figure 5]
Figure 5. Forest plot of comparison: 2 Gabapentin versus placebo, outcome: 2.1 Incidence of any pain at 3 months (all studies).
[Figure 6]
Figure 6. Forest plot of comparison: 3 Pregabalin versus placebo, outcome: 3.1 Incidence of any pain at 3 months follow-up (all studies).
[Analysis 1.1]
Analysis 1.1. Comparison 1 Ketamine versus placebo comparisons, Outcome 1 Incidence of any pain at 3 months (all studies).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Ketamine versus placebo comparisons, Outcome 2 Incidence of any pain at 3 months (drug administration ≤ 24 hours).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Ketamine versus placebo comparisons, Outcome 3 Incidence of any pain at 3 months (drug administration > 24 hours).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Ketamine versus placebo comparisons, Outcome 4 Incidence of any pain at 4 months.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Ketamine versus placebo comparisons, Outcome 5 Incidence of any pain at 6 months (all studies).
[Analysis 1.6]
Analysis 1.6. Comparison 1 Ketamine versus placebo comparisons, Outcome 6 Incidence of any pain at 6 months (drug administration ≤ 24 hours).
[Analysis 1.7]
Analysis 1.7. Comparison 1 Ketamine versus placebo comparisons, Outcome 7 Incidence of any pain at 6 months (drug administration > 24 hours).
[Analysis 1.8]
Analysis 1.8. Comparison 1 Ketamine versus placebo comparisons, Outcome 8 Incidence of Moderate or severe pain at 6 months.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Ketamine versus placebo comparisons, Outcome 9 Incidence of any pain at 12 months.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Gabapentin versus placebo, Outcome 1 Incidence of any pain at 3 months (all studies).
[Analysis 2.2]
Analysis 2.2. Comparison 2 Gabapentin versus placebo, Outcome 2 Incidence of any pain at 3 months (drug administration ≤ 24 hours).
[Analysis 2.3]
Analysis 2.3. Comparison 2 Gabapentin versus placebo, Outcome 3 Incidence of any pain at 3 months (drug administration > 24 hours).
[Analysis 2.4]
Analysis 2.4. Comparison 2 Gabapentin versus placebo, Outcome 4 Incidence of any pain at 6 months.
[Analysis 2.5]
Analysis 2.5. Comparison 2 Gabapentin versus placebo, Outcome 5 Mean Pain Score at 6 months (continuous data).
[Analysis 3.1]
Analysis 3.1. Comparison 3 Pregabalin versus placebo, Outcome 1 Incidence of any pain at 3 months follow up (all studies).
[Analysis 3.2]
Analysis 3.2. Comparison 3 Pregabalin versus placebo, Outcome 2 Incidence of any pain at 3 months (drug administration ≤ 24 hours).
[Analysis 3.3]
Analysis 3.3. Comparison 3 Pregabalin versus placebo, Outcome 3 Incidence of any pain at 3 months (drug administration > 24 hours).
[Analysis 3.4]
Analysis 3.4. Comparison 3 Pregabalin versus placebo, Outcome 4 Incidence of any pain at 6 months.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Pregabalin versus placebo, Outcome 5 Incidence of moderate to severe pain at 3 months.
[Analysis 3.6]
Analysis 3.6. Comparison 3 Pregabalin versus placebo, Outcome 6 Incidence of moderate to severe pain at 6 months.
[Analysis 3.7]
Analysis 3.7. Comparison 3 Pregabalin versus placebo, Outcome 7 Incidence of any pain at 12 months follow up.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Venlafaxine versus placebo comparisons, Outcome 1 Mean Pain Score at 6 months (continuous data).